Trustee Obligations When a Beneficiary Has a Substance Use Disorder

Last updated: 2026-03-05 · 8 sections

The Fiduciary Duty Framework

A trustee administering a trust for a beneficiary with a substance use disorder is holding two obligations that pull against each other. The duty of loyalty requires acting in the beneficiary's interest. The duty of prudence requires administering the trust with care and preserving it for all beneficiaries, including remainder interests. When a distribution would predictably fund active addiction, those duties diverge.^[1]

The law does not resolve this tension with a rule. It resolves it through the trust instrument, the applicable distribution standard, and the quality of the trustee's process. A trustee who documents a reasoned, informed decision is in a defensible position whether the outcome is favorable or not. A trustee who acts on instinct, or who defers indefinitely rather than deciding, is exposed regardless of intent.

Discretionary and Ascertainable Standards

The distribution standard governs how much latitude the trustee actually has.

• Ascertainable standard. Language directing distributions for health, education, maintenance, and support creates an argument that the trustee must fund treatment when the beneficiary requests it. Treatment is health. The harder question is whether the standard also obligates distributions for living expenses during active use.
• Purely discretionary standard. Language granting sole and absolute discretion gives the trustee authority to decline. That authority is broad but not unlimited: a trustee may not act arbitrarily, in bad faith, or without considering the beneficiary's circumstances at all.
• Incentive or conditional provisions. Some instruments condition distributions on documented treatment engagement, negative testing, or clinical attestation. Drafting approaches to behavioral health provisions in trust language vary considerably in how enforceable and how administrable they are.

The Uniform Law Commission publishes the model trust code adopted in substantial part by most states, and ACTEC maintains commentary addressing discretionary distribution questions of this kind.^[3]

When Evidence of Use Reaches the Trustee

A recurring scenario: the trustee learns, formally or informally, that the beneficiary has tested positive or has relapsed. The instinct is to suspend distributions immediately. That instinct is often wrong, or at least premature.

Suspending all support can remove housing, health coverage, and the stability that treatment engagement depends on, and it can accelerate exactly the outcome the trustee is trying to prevent. A structured response, of the kind set out in this framework for trustees facing a positive test, generally separates categories of spending rather than switching support off. Direct payment of rent, insurance premiums, and clinical care to the provider preserves stability while removing discretionary cash.

The distinction matters legally as well as practically. Paying a landlord directly is a distribution for maintenance. Handing over cash that funds use is harder to defend as prudent administration.

Obtaining Clinical Input the Trustee Can Rely On

Trustees are not clinicians and should not be making clinical judgments. The defensible path is to obtain an independent assessment and act on it. That requires a professional who reports to the trust rather than to a treatment facility with an admission to fill.

Engaging independent case management produces the documentation a trustee needs: an assessment of the current level of care, a treatment plan, and periodic confirmation of engagement. The related overview of how case management works describes what that engagement typically covers. Advisors and trustee teams commonly retain this function through firms that work directly with trust and estate counsel.

Confidentiality Limits on What the Trustee May Learn

A trustee cannot simply call a treatment program and ask how the beneficiary is doing. Substance use disorder records carry heightened federal protection under 42 CFR Part 2, which is more restrictive than HIPAA and generally requires the patient's written consent for disclosure.^[4][5]

The practical solution is a narrow, negotiated release executed by the beneficiary, authorizing disclosure of a defined set of facts: that the person is enrolled, the level of care, and whether they remain engaged. Clinical content stays out. This gives the trustee a factual basis for distribution decisions without converting the trustee into a party to the treatment.

Beneficiaries Who Are Minors

Where the beneficiary is an adolescent, the trustee's role usually runs through the parent or guardian rather than directly. Funding decisions may still fall to the trust, particularly for residential placement, which is expensive and frequently denied by commercial insurers. Trustees funding an adolescent placement should understand the levels of care being proposed and the distinction between therapeutic boarding schools and clinical residential treatment.

Placement at a distance also raises a logistics question that trusts are often asked to fund. Where a resistant adolescent must be moved to a program, families and fiduciaries increasingly evaluate structured therapeutic transport against the ethical considerations discussed in ethical teen treatment transport. The transport services overview covers what the service involves.

Documenting the Decision

Whatever the trustee decides, the file should show the reasoning. A defensible record generally contains the request, the trust language relied on, the independent clinical input obtained, the alternatives considered, the decision, and the rationale. Where the trustee declines a distribution, the record should show what was offered instead.

Trustees facing genuinely close questions, particularly where remainder beneficiaries may later object, can seek instruction from the court. This is slower and creates a record, but it converts a discretionary exposure into a supervised one.